TMCnet News

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals Inc. (BMRN)
[November 20, 2020]

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals Inc. (BMRN)


The Law Offices of Frank R. Cruz reminds investors of the upcoming November 24, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased BioMarin Pharmaceuticals Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) securities between February 28, 2020 and August 18, 2020, inclusive (the "Class Period").

If you are a shareholder who suffered a loss, click here to participate.

On August 19, 2020, the Company announced receipt of a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding BioMarin's Biologics License Application ("BLA") for valoctocogene roxaparvovec. Therein, the FDA determined that the "differences between Study 270-201 (Phase 1/2) and the Phase 3 study limited its ability torely on the Phase 1/2 study to support durability of effect." As a result, the FDA recommended that BioMarin "complete the Phase 3 Study and submit two-year follow-up safety and efficacy data on all study participants."



On this news, BioMarin's stock price fell $41.82 per share, or 35%, to close at $76.72 per share on August 19, 2020, thereby injuring investors.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (2) as a result, it was foreseeable that the FDA would not approve the BLA for valoctocogene roxaparvovec without further data; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.


Follow us for updates on Twitter (News - Alert): twitter.com/FRC_LAW.

If you purchased or otherwise acquired BioMarin securities during the Class Period, you may move the Court no later than November 24, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


[ Back To TMCnet.com's Homepage ]